No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects

Published:2012-06-07 Issue:10 Volume:14 Page:937-943
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Smulders R. A.¹,Zhang W.²,Veltkamp S. A.¹,Dijk J.¹,Krauwinkel W. J. J.¹,Keirns J.²,Kadokura T.³

Affiliation:

1. Global Clinical Pharmacology and Exploratory Development; Astellas Pharma Europe BV; Leiderdorp; The Netherlands

2. Global Clinical Pharmacology and Exploratory Development; Astellas Pharma Global Development, Inc; Northbrook; IL; USA

3. Clinical Pharmacology; Astellas Pharma Inc; Tokyo; Japan

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2012.01624.x/fullpdf

Reference18 articles.

1. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes;Nathan;Diabetes Care,2009

2. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability;Sirtori;Pharmacol Res,1994

3. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes;Korytkowski;Diabetes Care,2002

4. Pioglitazone: mechanism of action;Smith;Int J Clin Pract Suppl,2001

5. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4);Thornberry;Best Pract Res Clin Endocrinol Metab,2009

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium‐glucose co‐transporter 2 inhibitor and glimepiride in healthy Chinese male subjects;Journal of Clinical Pharmacy and Therapeutics;2022-03-31

2. Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor;Translational and Clinical Pharmacology;2020

3. Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes;Phytotherapy Research;2019-07-29

4. Sitagliptin Versus Ipragliflozin for Type 2 Diabetes in Clinical Practice;Journal of Endocrinology and Metabolism;2019

5. Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis;Experimental and Clinical Endocrinology & Diabetes;2018-06-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3